Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Update From Conclusion of COVID-19 Vaccine Study

<< Previous

Bullboard Posts

Next >>

Comment by PowerofNowon Feb 17, 2021 3:35pm

99 Views

Post# 32587213

RE:RE:Update From Conclusion of COVID-19 Vaccine Study

Exactly, the news release clearly states as well, " In this rapidly moving pandemic, variants have become the established infection model, which can be better addressed with Vaxils SP approach. Neutralizing antibody technologies may require frequent modifications, while Vaxils signal peptide technology may provide long-term efficacy as the virus mutates.

<< Previous

Bullboard Posts

Next >>

Two Venture-listed mining stocks file NI 43-101 reports